Burian Lawrence J.
CIK: 0001480437
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Knicks' role in Foot Locker's turnaround discussed. Recent coverage examines how the New York Knicks may support Foot Locker's efforts to improve its business performance. This is relevant to Madison Square Garden Sports Corp. because the Knicks are a major asset within the MSGS portfolio. While the news focuses on a partner's strategy, it highlights the broader commercial ecosystem surrounding the team.
this person other insiders at MSGS
Transaction History
| CNK | ▲ Buy | Grant | 3,908 | $0 | 8/12/2026 | View on chart |
| MSGS | ▲ Buy | Option Exercise | 2,280 | $0 | 9/15/2021 | View on chart |
| MSGS | ▼ Sell | Tax Withholding | 1,212 | $219K | 9/15/2021 | View on chart |
| MSGS | ▲ Buy | Option Exercise | 760 | $0 | 9/15/2021 | View on chart |
| MSGS | ▲ Buy | Option Exercise | 840 | $0 | 9/15/2021 | View on chart |
| MSGS | ▲ Buy | Option Exercise | 1,457 | $0 | 9/15/2021 | View on chart |
| MSGS | ▼ Sell | Tax Withholding | 1,623 | $293K | 9/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Cinemark stock rises on ScreenX expansion and higher Q3 revenue forecasts
Cinemark shares have gained 7.5% following announcements of ScreenX expansion and increased third-quarter revenue forecasts. The stock has also risen 12% over the past month, with analysts noting its premium format growth. Current trading levels remain below the average analyst target price of $40.27.
Cinemark stock rises on ScreenX expansion and higher Q3 revenue forecasts. Cinemark shares have gained 7.5% following announcements of ScreenX expansion and increased third-quarter revenue forecasts. The stock has also risen 12% over the past month, with analysts noting its premium format growth. Current trading levels remain below the average analyst target price of $40.27.